|
 |
European Pharmaceutical Contractor
|
The Scope of the Problem
Non-compliance commonly refers to the failure of patients to take medicines in their prescribed manner. Recognised as a serious health care issue, studies show that patient non-compliance can range from 20-80 per cent depending on the type of treatment being taken (1). The problem of non-compliance is not a new one and has been investigated for several decades worldwide.
The Consequences
Patient non-compliance lessens the quality of health care and can lead to dangerous consequences for patients. In the US, it has been estimated that non-compliance causes 340 deaths per day and is responsible for 10-25 per cent of hospital and nursing home admissions. Patient non-compliance is taken so seriously in the US that the New York Times dubbed it the nation's 'other drug problem' (2).
In a recent study conducted by Dendrite's Analytika Division, based on an analysis of data from nearly half of the US retail chain and independent companies, it was discovered that 'fewer than one in four patients on a cholesterol-lowering therapy completes a full year of treatment' (3). For the pharma industry, this gap between compliance and persistence translates into vast amounts of lost revenue.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Pietro Bonacossa, Marketing Executive, and Dr Faiz Kermani, Budgets, Proposals and Marketing Executive at Chiltern International Inc
Pietro Bonacossa is a Marketing Executive at Chiltern International in the USA. He holds a BA degree in International Trade from Auburn University and an MBA in Marketing from Georgia State University. Prior to joining Chiltern, he spent two years at Turner Broadcasting Systems, working as a Project Co-ordinator for CNN Headline News and as a Public Relations Liaison for CNN.com.
Dr Faiz Kermani is currently a Budgets, Proposals & Marketing Executive working in business development at Chiltern International. He previously worked in business development at CMR International, examining R&D productivity issues for pharmaceutical industry clients. He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a First Class honours degree in Pharmacology with Toxicology from King's College, London.
|
|
|
|
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
